High Burden of Subclinical Cardiovascular Target Organ Damage After Pediatric Liver Transplantation

Nima Memaran, Bianca Borchert‐Mörlins, Bernhard M. W. Schmidt, Rizky I. Sugianto, Hannes Wilke, Ricarda Blöte, Ulrich Baumann, Elena Bauer, Anika von Wick, Norman Junge, Christoph Leiskau, Eva D. Pfister, Daniela Thurn‐Valsassina, Nicolas Richter, Imeke Goldschmidt, Anette Melk – 11 February 2019 – Cardiovascular (CV) events account for 8%‐13% of deaths after liver transplantation (LT) in adulthood. Although CV risk factors (RFs) are present, little is known about the prevalence of subclinical CV target organ damage (TOD) in children after LT.

Use of Steatotic Grafts in Liver Transplantation: Current Status

Ana I. Álvarez‐Mercado, José Gulfo, Manuel Romero Gómez, Mónica B. Jiménez‐Castro, Jordi Gracia‐Sancho, Carmen Peralta – 10 February 2019 – In the field of liver transplantation, the demand for adequate allografts greatly exceeds the supply. Therefore, expanding the donor pool to match the growing demand is mandatory. The present review summarizes current knowledge of the pathophysiology of ischemia/reperfusion injury in steatotic grafts, together with recent pharmacological approaches aimed at maximizing the utilization of these livers for transplantation.

Liver Transplant in Colombia

Maria‐Angélica Salinas Nova, Ángela Rojas Meneses, Juan‐Carlos Restrepo Gutierrez – 8 February 2019 – Liver transplantation began in Colombia in 1979. It is one of the most active countries in this field in Latin America but has faced problems with the regulation and appropriate management of solid organ transplantations, including transplant tourism, which is a worldwide problem. There is a well‐structured donation and transplant network regulated by the government in all the stages of the process.

Bezafibrate Improves GLOBE and UK‐PBC Scores and Long‐Term Outcomes in Patients With Primary Biliary Cholangitis

Akira Honda, Atsushi Tanaka, Tetsuji Kaneko, Atsumasa Komori, Masanori Abe, Mie Inao, Tadashi Namisaki, Naoaki Hashimoto, Kazuhito Kawata, Atsushi Takahashi, Masashi Ninomiya, Jong‐Hon Kang, Mie Arakawa, Satoshi Yamagiwa, Satoru Joshita, Takeji Umemura, Ken Sato, Akira Kaneko, Kentaro Kikuchi, Jun Itakura, Takako Nomura, Keisuke Kakisaka, Hideki Fujii, Norifumi Kawada, Yasuhiro Takikawa, Tsutomu Masaki, Hiromasa Ohira, Satoshi Mochida, Hitoshi Yoshiji, Satoshi Iimuro, Yasushi Matsuzaki, Hajime Takikawa, Japan PBC Study Group – 8 February 2019 – In Japan, bezafibrate (BF) is a second‐line ag

Axis inhibition protein 1 (Axin1) Deletion–Induced Hepatocarcinogenesis Requires Intact β‐Catenin but Not Notch Cascade in Mice

Yu Qiao, Jingxiao Wang, Eylul Karagoz, Binyong Liang, Xinhua Song, Runze Shang, Katja Evert, Meng Xu, Li Che, Matthias Evert, Diego F. Calvisi, Junyan Tao, Bruce Wang, Satdarshan P. Monga, Xin Chen – 8 February 2019 – Inactivating mutations of axis inhibition protein 1 (AXIN1), a negative regulator of the Wnt/β‐Catenin cascade, are among the common genetic events in human hepatocellular carcinoma (HCC), affecting approximately 10% of cases.

Mac‐2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection

Tomi Jun, Yao‐Chun Hsu, Shintaro Ogawa, Yen‐Tsung Huang, Ming‐Lun Yeh, Cheng‐Hao Tseng, Chung‐Feng Huang, Chi‐Ming Tai, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu, Yasuhito Tanaka, Mindie H. Nguyen – 8 February 2019 – Mac‐2 binding protein glycosylation isomer (M2BPGi) is a novel glycoprotein biomarker that correlates with liver fibrosis. It has been investigated in East Asian populations as a hepatocellular carcinoma (HCC) biomarker.

Subscribe to